Altre lingue Elutia Inc.

Azioni

ELUT

US05479K1060

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
3,8 ^USD	-2,81%		+16,21%	+75,93%

21/06	ELUTIA INC. : Lake Street ancora positivo	ZM
20/06	ELUTIA INC. : Cantor Fitzgerald conferma il rating Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators	17/06
Elutia Announces $13.26 Million Registered Direct Offering	17/06
Elutia Inc. Announces FDA Clearance of EluPro®	17/06
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024	13/05
Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Elutia : Q1 2024 Financial Results Presentation	09/05
Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M	09/05
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance	09/05
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024	02/05
Elutia Planet MicroCap Showcase: VEGAS 2024 Presentation	02/05
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1	24/04
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M	07/03
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024	07/03
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024	22/02
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants	20/02
Elutia Regains Compliance with Nasdaq Listing Requirements	10/01
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance	18/12
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance	18/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Elutia Inc.

Azioni

ELUT

US05479K1060

Altre lingue

Filtri